Bristol Myers Squibb Reports Strong Q1 2026 Earnings and Confirms Growth Strategy Post-Karuna Acquisition

Bristol Myers Squibb (BMY) exceeded Wall Street expectations with first-quarter revenue of $11.5 billion, marking a year-on-year increase of 2.6%, and adjusted earnings per share of $1.58 that outperformed analyst estimates. The company reaffirmed its 2026 revenue guidance of $46.75 billion, slightly below market forecasts, while also highlighting strong contributions from its major product, Eliquis, which generated $4.14 billion. This positive financial performance follows the strategic $14 billion acquisition of Karuna Therapeutics, further solidifying BMY's growth trajectory in the biotechnology sector despite a slight dip in its operating margin.